Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACTICORT vs ADVAIR DISKUS 100/50
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.
Fluticasone propionate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, thereby inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production. Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase, increasing c AMP levels, leading to bronchodilation and inhibition of mast cell mediator release.
Corticosteroid-responsive dermatoses (e.g., eczema, psoriasis, contact dermatitis),Off-label: atopic dermatitis, lichen planus, discoid lupus erythematosus
Long-term maintenance treatment of asthma in patients aged 4 years and older,Maintenance treatment of chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis,Off-label: Treatment of COPD exacerbations
5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.
One inhalation (100 mcg fluticasone propionate and 50 mcg salmeterol) twice daily, approximately 12 hours apart, via oral inhalation.
1.5-2.5 hours; prolonged in hepatic impairment (up to 10 hours) and renal impairment (up to 6 hours)
Fluticasone propionate: terminal half-life approximately 8 hours (range 4-12 hours) after inhalation; clinical context: supports twice-daily dosing. Salmeterol: terminal half-life approximately 5.5 hours (range 3-10 hours) after inhalation; clinical context: supports twice-daily dosing.
Hepatic metabolism via CYP3A4; inactive metabolites excreted renally and biliary.
Fluticasone propionate undergoes extensive first-pass metabolism via cytochrome P450 3A4 (CYP3A4) to an inactive carboxylic acid metabolite. Salmeterol is metabolized primarily by CYP3A4 to alpha-hydroxysalmeterol.
Renal (70% as unchanged drug and metabolites), biliary/fecal (30%)
Fluticasone propionate: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (~5% unchanged), fecal elimination of parent drug and metabolites. Salmeterol: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (about 25% of dose), fecal elimination.
90% bound to albumin and corticosteroid-binding globulin
Fluticasone propionate: approximately 90% bound to plasma proteins (primarily albumin). Salmeterol: approximately 96% bound to plasma proteins (primarily albumin and alpha-1-acid glycoprotein).
1.2-1.5 L/kg; indicates extensive tissue distribution
Fluticasone propionate: Vd approximately 4.2 L/kg (range 3-6 L/kg), indicating extensive tissue distribution. Salmeterol: Vd approximately 7 L/kg (range 5-10 L/kg), indicating extensive tissue distribution.
Oral: 80-90%; IM: 100%
Fluticasone propionate: absolute bioavailability from inhaled ADVAIR DISKUS is approximately 18% (range 15-21%), due to lung deposition and low oral bioavailability (<1%). Salmeterol: absolute bioavailability from inhaled ADVAIR DISKUS is approximately 25% (range 20-30%), due to lung deposition; oral bioavailability is negligible.
No dose adjustment necessary for acute use; for chronic therapy in severe renal impairment (e GFR <30 m L/min/1.73 m2), consider dose reduction by 50% to minimize mineralocorticoid effects.
No dosage adjustment required for renal impairment; pharmacokinetics not significantly altered.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75% due to reduced clearance.
Child-Pugh Class A: No adjustment. Child-Pugh Class B and C: Use with caution; consider reduced dose due to increased systemic exposure; monitor for adverse effects.
0.05-2 mg/kg/day orally divided every 6-8 hours, not to exceed 80 mg/day; adjust based on response and severity.
Not recommended for children under 12 years. For adolescents 12 years and older, same as adult dosing: 1 inhalation twice daily.
Initiate at lowest effective dose (e.g., 5 mg/day) and titrate slowly due to increased risk of osteoporosis, glucose intolerance, and immunosuppression; monitor for adverse effects.
No specific dose adjustment; use lowest effective dose; monitor for systemic corticosteroid effects and cardiovascular events due to salmeterol.
None
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. Therefore, ADVAIR DISKUS 100/50 should only be used for asthma in patients not adequately controlled on a long-term asthma control medication (e.g., inhaled corticosteroid) or whose disease severity warrants initiation of both an inhaled corticosteroid and a LABA.
HPA axis suppression with prolonged use or large surface area,Local irritation and skin atrophy,Systemic absorption with occlusive dressings,Potential for rebound effects after discontinuation
Increased risk of asthma-related death with LABA use,Cardiovascular effects (e.g., increased blood pressure, tachycardia, arrhythmias),Paradoxical bronchospasm,Hypersensitivity reactions (e.g., anaphylaxis, angioedema),Hypercorticism and adrenal suppression with high doses or prolonged use,Reduced bone mineral density with long-term use,Pneumonia risk in COPD patients,Ketoacidosis in patients with diabetes
Known hypersensitivity to components,Untreated bacterial/fungal infections,Viral skin infections (e.g., herpes simplex, varicella),Perioral dermatitis, rosacea
Primary treatment of status asthmaticus or acute episodes of asthma requiring intensive measures,Hypersensitivity to fluticasone propionate, salmeterol, or any excipient,Severe hypersensitivity to milk proteins (due to lactose content)
No clinically significant food interactions. Alcohol may increase systemic absorption if tympanic membrane is perforated, but generally avoid alcohol-based ear drops if perforation suspected.
No specific food interactions; avoid grapefruit juice as it may increase fluticasone systemic absorption. Take with or without food.
First trimester: Increased risk of cleft palate and cardiac defects (OR 1.3-3.5). Second/third trimesters: Risk of fetal growth restriction, adrenal suppression, and oligohydramnios with chronic use. Avoid use unless maternal benefit outweighs risks.
Pregnancy Category C. Fluticasone propionate and salmeterol: No adequate human studies. In animal studies, fluticasone caused fetal toxicity at high doses (cleft palate, reduced fetal weight) at doses ≥30 mcg/kg SC; salmeterol caused delayed ossification and reduced survival at doses ≥1.4 mg/kg PO. First trimester: No data for ADVAIR; avoid unless benefit outweighs risk. Second/third trimester: Use only if clearly needed; monitor fetal growth and consider risk of maternal asthma exacerbation.
Prednisone enters breast milk at low levels (M/P ratio ~0.1-0.3). At maternal doses ≤20 mg/day, the infant dose is <10% of maternal weight-adjusted dose. Consider risk of adrenal suppression in infant with high-dose, long-term therapy. AAP rates as compatible with breastfeeding.
Fluticasone and salmeterol are excreted in breast milk in animals; unknown in humans. M/P ratio not determined. Consider developmental benefits of breastfeeding vs. potential for drug-induced adverse effects. Use caution if benefit to mother outweighs infant risk. For asthma, inhaled doses likely produce minimal systemic exposure, but monitor infant for respiratory symptoms or heart rate changes.
No empirical dose adjustment required; however, pharmacokinetic changes (increased Vd, hepatic metabolism) may reduce efficacy. Doses may need to be increased by 20-30% in third trimester if disease activity increases. Taper to lowest effective dose.
No specific dose adjustments are recommended for ADVAIR DISKUS 100/50 during pregnancy. However, pregnancy may alter pharmacokinetics: increased clearance of fluticasone and salmeterol due to elevated blood volume and renal blood flow. Monitor asthma control closely; if deterioration occurs, consider increasing dose or adding other controller therapy. Do not exceed maximum recommended dose (500/50 twice daily).
ACTICORT (hydrocortisone/neomycin/polymyxin B) is a topical combination used for inflammatory ear conditions. Avoid prolonged use (>10 days) to prevent sensitization and overgrowth of non-susceptible organisms. Tympanic membrane perforation is a contraindication due to ototoxicity risk. Use the otic solution not the ophthalmic suspension for ear infections.
ADVAIR DISKUS 100/50 (fluticasone propionate 100 mcg/salmeterol 50 mcg) is a combination inhaler for maintenance therapy of asthma or COPD; not for acute bronchospasm. Rinse mouth after use to prevent oral candidiasis. Monitor for increased blood pressure, tachycardia, and hypokalemia due to salmeterol. Do not use as monotherapy in asthma without inhaled corticosteroid; salmeterol increases risk of asthma-related death when used alone. Diskus device delivers medication via a breath-activated dry powder; ensure patient breaths in rapidly and deeply.
Instill drops while lying down with affected ear upward, then remain in position for 5 minutes.,Do not touch dropper to ear or any surface to avoid contamination.,Complete full course even if symptoms improve; do not use longer than prescribed.,Report worsening redness, swelling, or hearing loss immediately.,Avoid getting water in ear during treatment; use a cotton ball soaked in petroleum jelly to protect ear when showering.
Use exactly as prescribed; do not use more puffs than directed.,Rinse mouth with water after each use (do not swallow) to prevent thrush.,Do not use for sudden breathing problems; have a rescue inhaler (e.g., albuterol) available.,If you miss a dose, skip it; do not double the dose.,Call your doctor if symptoms worsen or you need more rescue inhaler than usual.,Store diskus at room temperature away from moisture and heat; keep closed when not in use.,Do not stop taking this medicine without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACTICORT vs ADVAIR DISKUS 100/50, answered by our medical review team.
ACTICORT is a Corticosteroid that works by Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production and inflammatory mediators via glucocorticoid receptor binding.. ADVAIR DISKUS 100/50 is a Corticosteroid/LABA Combination that works by Fluticasone propionate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, thereby inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production. Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase, increasing c AMP levels, leading to bronchodilation and inhibition of mast cell mediator release.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACTICORT and ADVAIR DISKUS 100/50 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACTICORT is: 5-60 mg orally once daily, or divided twice daily, depending on condition severity and response.. The standard adult dose of ADVAIR DISKUS 100/50 is: One inhalation (100 mcg fluticasone propionate and 50 mcg salmeterol) twice daily, approximately 12 hours apart, via oral inhalation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACTICORT and ADVAIR DISKUS 100/50 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACTICORT is classified as Category C. First trimester: Increased risk of cleft palate and cardiac defects (OR 1.3-3.5). Second/third trimesters: Risk of fetal growth restriction, adrenal suppression, and oligohydramnio. ADVAIR DISKUS 100/50 is classified as Category C. Pregnancy Category C. Fluticasone propionate and salmeterol: No adequate human studies. In animal studies, fluticasone caused fetal toxicity at high doses (cleft palate, reduced fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.